ArticlePharmacoepidemiology and drug safety2025
The Effect of Use of Tricyclic Antidepressants or Serotonin-Norepinephrine Reuptake Inhibitors Versus Selective Serotonin Reuptake Inhibitors on the Risk of Urinary Tract Infection Among People With Multiple Sclerosis: A Nested Case-Control Study.
Article in Pharmacoepidemiology and drug safety, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Validation of an AI-Assisted Framework for Systematic Bias Assessment in Observational Studies.Journal of evaluation in clinical practice · 2026Article
- The Effect of Use of Tricyclic Antidepressants or Serotonin-Norepinephrine Reuptake Inhibitors Versus Selective Serotonin Reuptake Inhibitors on the Risk of Urinary Tract Infection Among People With Multiple Sclerosis: A Nested Case-Control Study.Pharmacoepidemiology and drug safety · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo study the effect of tricyclic antidepressant (TCA)/selective serotonin-norepinephrine reuptake inhibitor (SNRI) versus selective serotonin reuptake inhibitor (SSRI) on the risk of urinary tract infection (UTI) among people with multiple sclerosis (MS).
methodsA case-control study was conducted using data from the UK Clinical Practice Research Datalink Aurum, nested within a cohort of people with MS. Each person with a UTI was matched to ≤ 4 controls on sex, region, age (±2 years), and time since MS diagnosis (±20%). Conditional logistic regression analyses were conducted to calculate adjusted odds ratios (aORs) with 95% confidence intervals (CIs) to compare TCA/SNRI to SSRI use and each antidepressant group to no antidepressant use. ORs were adjusted for smoking status, BMI, comorbidities, and recent drug prescriptions.
resultsTwo thousand six hundred and sixty-four cases were matched to 3722 controls. TCA/SNRI versus SSRI use did not increase the risk of UTI (conditional aOR 1.21 [95% CI: 0.84-1.75]). TCA/SNRI use versus no antidepressant use did show an increased risk (conditional aOR [95% CI: 1.43 [1.21-1.69]), but SSRI versus no use did not (conditional aOR 1.15 [0.96-1.37]).
conclusionsThis study showed no increased risk of UTI for TCA/SNRI versus SSRI use among people with MS. However, effect estimates were imprecise due to small sample sizes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.